Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03052413 · ClinicalTrials.gov registry record · NA
Study to Evaluate a Nutraceutical Supplement for Treatment of Hair Loss and Thinning in Females
A NA study, sponsored by Sadick Research Group.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT03052413: Completed NA study, sponsored by Sadick Research Group.
NCT03052413 is a NA study that has completed, run by Sadick Research Group. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03052413, a NA study, has completed, sponsored by Sadick Research Group.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The objective of this study is to assess the safety and effectiveness of a nutraceutical supplement for the treatment of hair loss and thinning in females over the course of six months of continuous daily use.
Primary Outcome
change in hair density over the course of the study assessed by hair count
Interventions
- DIETARY_SUPPLEMENT placebo
- DIETARY_SUPPLEMENT Nutrafol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-12 |
| Est. Completion | 2017-11-10 |
| Phase | NA |
What the finished NCT03052413 record still lists
NCT03052413 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT03052413 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03052413 about?
NCT03052413 is a clinical study titled "Study to Evaluate a Nutraceutical Supplement for Treatment of Hair Loss and Thinning in Females". The objective of this study is to assess the safety and effectiveness of a nutraceutical supplement for the treatment of hair loss and thinning in females over the course of six months of continuous daily use.
What is the current status of trial NCT03052413?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2016-12. Estimated completion is 2017-11-10.
What interventions are being tested in trial NCT03052413?
The interventions under investigation include: placebo (DIETARY_SUPPLEMENT), Nutrafol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03052413?
This trial is sponsored by Sadick Research Group, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03052413's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia